Trends in Formulation October 2025 eBook

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.